Skip to main content

Table 2 Duodenal mRNA levels of selected genes

From: Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls

    n Messenger RNA
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCND1 CTNNB1 GSTP1
Patient controls    16 0.04 (0.03-0.06) 0.05 (0.04-0.07) 16.43 (11.54-22.14) 0.73 (0.52-1.12) 38.24 (27.25-51.76) 5.31 (4.14-6.77) 4.20 (2.71-5.95) 26.90 (21.88-36.03) 9.69 (6.37-15.60)
Patients with FAP Total Pre-intervention 37 0.05 (0.03-0.24) 0.04 (0.03-0.05) 13.36 (10.82-15.73) 0.71 (0.48-0.95) 28.16 (21.62-37.90) 3.30 (2.46-4.68) 3.72 (3.03-4.69) 24.84 (19.02-28.45) 7.64 (5.70-10.71)
Group A: Celecoxib & UDCA Pre-intervention 19 0.04 (0.02-0.28) 0.04 (0.03-0.06) 13.54 (10.90-18.51) 0.74 (0.54-1.05) 30.30 (23.16-36.54) 3.30 (2.47-5.21) 3.96 (2.63-4.72) 25.89 (19.80-31.89) 7.59 (5.78-11.07)
Post-intervention 14 0.04 (0.02-0.23) 0.04 (0.03-0.05) 13.72 (10.46-15.21) 0.63 (0.50-1.28) 27.13 (21.28-33.30) 3.20 (2.88-4.11) 3.50 (2.81-5.24) 24.05 (20.96-30.27) 7.36 (6.22-10.47)
Group B: Celecoxib & placebo Pre-intervention 18 0.09 (0.03-0.22) 0.03 (0.02-0.05) 11.66 (10.28-15.42) 0.63
(0.45-0.87)
27.96 (19.84-39.44) 3.30 (2.42-4.43) 3.63 (3.18-4.63) 21.60 (18.63-27.89) 7.73 (5.46-10.27)
Post-intervention 13 0.24 (0.05-0.84) 0.05 (0.03-0.08) 14.08 (10.79-16.87) 0.78 (0.58-1.20) 31.74 (21.02-47.12) 2.94 (2.58-4.83) 4.56 (3.09-5.56) 25.26 (19.93-33.62) 10.82 (7.44-16.18)
  1. Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; β2M, beta-2-microglobulin; COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome proliferative activated receptor delta; GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, glutathione S-transferase P1.
  2. Levels are expressed as median percentage relative to the mRNA level of the housekeeping gene β2M, set at 100%. Values are expressed as mean with 25 and 75 percentiles. For p-values of statistical analyses comparing mRNA levels of selected genes, see Table 3.